Amgen (AMGN) Drug Pipeline
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Amgen Inc (MX:AMGN) have in its pipeline
Amgen MX:AMGN is currently developing the following drugs: Semaglutide, Maridebart Cafraglutide, Amg 133, Romosozumab, Autoinjector, Evolocumab, Routine Lipid Management, Tarlatamab, Imdelltra, Amg 691, Romiplostim, Predniso Ne, Maridebart Cafraglutide, Amg 133, Aflibercept 8 Mg, Abp 938 8 Mg, Eylea Hd, Standard Of Care, Inebilizumab, Amg 127, Evolocumab Drug Substance A, Evolocumab Drug Substance B, Durvalumab, Tarlatamab, Zl-1310, Imdelltra, Coc, Maridebart Cafraglutide, Amg 133, Xaluritamig, Amg 509, Amg 732, Amg 133, Amg 436, Methotrexate, Pegloticase, Mtx, Vitamin D, Calcium, Maridebart Cafraglutide, Olpasiran, Moxifloxacin, Maridebart Cafraglutide, Blinatumomab, Hypercvad, Inebilizumab, Docetaxel, Abiraterone Acetate, Cabazitaxel, Xaluritamig, Sotorasib, Panitumumab, Teprotumumab, Abiraterone, Darolutamide, Xaluritamig, Blinatumomab, Pembrolizumab, Panitumumab, Amg 410. These drug candidates are in various stages of clinical development as the company works toward FDA approval.